Substituted aminoquinoxalines as tyrosine threonine kinase inhibitors

US9340528B2 · kind B2 · utility

Assignee

• Bayer Pharma Aktiengesellschaft · DE

Inventors

• Benjamin Bader · Berlin, DE
• Ulf Bömer · Glienicke, DE
• Stuart Ince · Berlin, DE
• Marcus Koppitz · Berlin, DE
• Philip Lienau · Berlin, DE
• Tobias Marquardt · Wuppertal, DE
• Duy Nguyen · Berlin, DE
• Stefan Prechtl · Berlin, DE
• Gerhard Siemeister · Berlin, DE
• Christof Wegscheid-Gerlach · Marburg, DE

Key dates

• Filing date: Aug 24, 2010
• Grant date: May 17, 2016
• Expiry date: Aug 24, 2030

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D487/04
• WIPO field: Organic fine chemistry
• WIPO sector: Chemistry

Abstract

The present invention relates to substituted aminoquinoxaline compounds of general formula (I) in which (II), R2, R3, R4, R6, R7, n and m are as given in the description and in the claims, to methods of preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds, to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, as well as to intermediate compounds useful in the preparation of said compounds.